Study on the efficacy of Agomelatine in patients with Parkinson disease with sleep disorders
Objective To investigate the clinical effect of Agomelatine on patients with Parkinson disease(PD)with sleep disorders.Methods A total of 100 patients with PD with sleep disorders admitted to the Department of Neurology,Nanjing Drum Tower Hospital Group Suqian Hospital from September 2022 to July 2023 were selected.According to the random number table method,they were divided into two groups,with 50 cases in each group.The control group was treated with Levodopa and Benserazide Tablets,and observation group was treated with Agomelatine on the basis of control group for four weeks.The scores of Parkinson disease sleep scale-2(PDSS-2),Pittsburgh sleep quality index(PSQI),rapid eye movement sleep behavior disorder screening questionnaire-Hong Kong edition(RBDQ-HK),self-rating anxiety scale(SAS),and self-rating de-pression scale(SDS)were compared between two groups before and after treatment;sleep latency,sleep efficiency,the proportion of each sleep stage,rapid eye movement(REM)latency,and R period periodic leg movement index(PLMI)were compared between two groups before and after treat-ment;and the occurrence of adverse reactions during treatment was recorded.Results After treatment,the scores of PDSS-2,PSQI,and RBDQ-HK in two groups were lower than those before treatment,and those in observation group were lower than those in control group(P＜0.05).After treat-ment,the sleep latency and REM latency of control group were shorter than those before treatment,and PLMI was lower than that before treatment,the proportion of R sleep stage was higher than that before treatment(P＜0.05);sleep latency and REM latency in observation group were shorter than those before treatment,PLMI was lower than that before treatment,and sleep efficiency,the proportion of N2 sleep stage,and the proportion of R sleep stage were higher than those before treatment(P＜0.05).After treatment,sleep latency and REM latency in observation group were shorter than those in control group,PLMI was lower than that in control group;sleep efficiency,the proportion of N2 sleep stage,and the proportion of Rsleep stage were higher than those in control group(P＜0.05).After treatment,SAS and SDS scores of two groups were lower than those before treatment,and those in observation group were lower than those in control group(P＜0.05).The total incidence of adverse reactions in observation group was lower than that in control group(P＜0.05).Conclusion Levodopa and Benserazide Tables combined with Agomelatine helps to improve sleep quality in PD patients with sleep disorders.
Levodopa and Benserazide TabletsAgomelatineParkinson disease with sleep disordersSleep latencySleep quality
NETL
NSTL
万方数据
